Drug Profile
Research programme: monoclonal antibody therapeutics - Staurus Pharma
Alternative Names: Anti SpA-variant IgG1; Staurus 001Latest Information Update: 18 Sep 2023
Price :
$50
*
At a glance
- Originator Staurus Pharma
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action Cell adhesion molecule modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Staphylococcal infections
Most Recent Events
- 18 Sep 2023 Preclinical development for Staphylococcal infections is ongoing in the US (Staurus Pharma pipeline, September 2023)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Staphylococcal-infections in USA
- 16 Sep 2016 Research progarmme: monoclonal antibody therapeutics - Staurus Pharma is available for licensing as of 16 Sep 2016. http://www.stauruspharma.com/